0

Histidine Supplementation for Alzheimer's Disease

WR
Overseen ByWells Reynolds, MD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Wake Forest University Health Sciences
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for Alzheimer's disease.Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months. Baseline evaluation and followup evaluation at 3 months postop.

Research Team

WR

Wells Reynolds, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

This trial is for individuals with Alzheimer's Disease who are interested in testing whether a dietary supplement, l-Histidine, can improve their cognitive function. Participants will be randomly assigned to receive either the Histidine supplement or a placebo for three months.

Inclusion Criteria

Live at home currently
I am 50 years old or older.
Clinical Dementia Score of 3.0 or higher

Exclusion Criteria

Psychiatric

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either Histidine or placebo for up to 3 months, with titrated dosing of L-histidine in the treatment arm

3 months
Baseline evaluation, 3-month clinic visit

Follow-up

Participants are monitored for safety and effectiveness after treatment, with cognitive testing and lab evaluations

9 months
1-year clinic visit

Treatment Details

Interventions

  • Histidine Oral Supplementation
Trial Overview The study is examining if taking l-Histidine orally can boost brain health and cognition in Alzheimer's patients by increasing certain substances that may help blood flow and brain repair. Patients will take the supplement or placebo over three months with evaluations before and after.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: Treatment-HistidineActive Control1 Intervention
Treatment-Histidine
Group II: ControlPlacebo Group1 Intervention
Control

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials
1,432
Recruited
2,506,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security